Disease · MONDO_0005062
Comparisons in its trials63
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 63
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 16 of 49 | 47 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Non-Relapse Mortality Rate (NRM) | 2 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 29 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: deaths from any cause | 31 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: serious adverse events | 6 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
| NiCord® (Omidubicel) vs Unmanipulated CBU(s): First Grade 2/3 Bacterial or Invasive Fungal Infections by 100 Days Following Transplantation | 24 of 62 | 38 of 63 | 125 | NCT02730299 | Trial comparisons |
| NiCord® (Omidubicel) vs Unmanipulated CBU(s): Number of Participants With Platelet Engraftment by 42 Days Post-transplantation | 34 of 62 | 22 of 63 | 125 | NCT02730299 | Trial comparisons |
| T Cell Depletion Transplant Participants vs Stem Cell Donors: deaths from any cause | 14 of 58 | 0 of 58 | 116 | NCT00378534 | Trial comparisons |
| T Cell Depletion Transplant Participants vs Stem Cell Donors: serious adverse events | 14 of 58 | 0 of 58 | 116 | NCT00378534 | Trial comparisons |
| BeEAM vs BEAM: deaths from any cause | 4 of 53 | 6 of 55 | 108 | NCT02278796 | Trial comparisons |
| BeEAM vs BEAM: serious adverse events | 6 of 53 | 6 of 55 | 108 | NCT02278796 | Trial comparisons |
| Omidubicel vs Unmanipulated CBU(s): deaths from any cause | 19 of 52 | 24 of 56 | 108 | NCT02730299 | Trial comparisons |
| Omidubicel vs Unmanipulated CBU(s): serious adverse events | 47 of 52 | 51 of 56 | 108 | NCT02730299 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: Number of Participants With Engraftment | 45 of 52 | 44 of 53 | 105 | NCT00067002 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: serious adverse events | 9 of 52 | 4 of 53 | 105 | NCT00067002 | Trial comparisons |
| BeEAM vs BEAM: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%. | 8 of 51 | 11 of 52 | 103 | NCT02278796 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: Rate of Acute Graft Versus Host Disease (GVHD) | 29 of 45 | 24 of 44 | 89 | NCT00067002 | Trial comparisons |
| Phase 1b/2: Follicular Lymphoma Expansion Cohort: vs Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:: deaths from any cause | 6 of 27 | 24 of 34 | 61 | NCT02401048 | Trial comparisons |
| Phase 1b/ 2: Follicular Lymphoma Expansion Cohort vs Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort: Phase 1b/2 : Overall Response Rate of Number of Participants | 7 of 27 | 8 of 34 | 61 | NCT02401048 | Trial comparisons |
| Phase 1b/2: Follicular Lymphoma Expansion Cohort: vs Phase 1b/ 2: Diffuse Large B-cell Lymphoma Expansion Cohort:: serious adverse events | 10 of 27 | 23 of 34 | 61 | NCT02401048 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005062/comparisons